The distribution of MACCEs probabilities of 5 treatments being ranked at possible positions.
- Xiaoxuan Gong (4510408)
- Shaowen Tang (285536)
- Jiangjin Li (4510411)
- Xiwen Zhang (278662)
- Xiaoyi Tian (4510414)
- Shuren Ma (3663361)
Publication date
October 2017
DOIAbstract
<p>MACCEs, main adverse cardiac and cerebrovascular events; DAPT, dual-antiplatelet therapy; Riva15 + P2Y<sub>12</sub>, rivaroxaban 15 mg/d plus P2Y<sub>12</sub> inhibitor; Riva2.5 + P2Y<sub>12</sub>, rivaroxaban 2.5 mg bid plus P2Y<sub>12</sub> inhibitor; TT, triple-antiplatelet therapy; VKA, vitamin K antagonist; SAPT, single antiplatelet therapy.</p
Add to ORKG